Formerly Summit Biosciences Inc. | KDD’s Post

Delve into a discussion with experts from FDA and industry about MIDD Strategies in RNA-Based Oligonucleotide Drug Development in this upcoming #ASCPTwebinar. 4/24 at 12 pm ET: https://bit.ly/49MdUxw

Thoughts on this? >> Novartis hands PeptiDream $180M upfront to extend radiopharma discovery pact >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #biotech #pharma #pharmaceutical

For my friends and colleagues in the world of oligonucleotide drug development, here's a recent draft guideline from the EMA that you may find useful.

Top 10 most anticipated drug launches of 2024! 🌟 Curious about who's made the list? 👀 Check out this list highlighting the biggest potential new drugs of the year for 2024 😎 Are there any notable ones missing❓ #LifeSciences #DrugLaunches2024 #Pharmacutical #BioTech

Thoughts on this? >> SK Bioscience takes majority stake in CDMO for $244M; Ex-Lonza CEO joins Cytiva >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #pharma #productmarketing

Check out this article by Informist Newswire featuring our CFO and Executive Director, Sibaji Biswas. It highlights how Syngene is poised to benefit from shifts in the global pharmaceutical landscape, including supply chain realignment away from China and the US Inflation Reduction Act. The article highlights our anticipation of strong demand, strategic initiatives, and robust capabilities in large molecule production. Sibaji also emphasizes Syngene's alternative supply chain options, offering clients a choice between a China-independent source or a cost-competitive China-based option. 👉Read the full article here (link in comments). #Syngene #CDMO #Biopharma

There are many emerging Biopharmas listed here. To me it looks totally different from what was 10 years, or even 5 years ago. "The top 10 list is based on Evaluate’s 2024 preview, where the analysts assess what they see as the biggest-selling drugs that will be approved this year in terms of sales by 2028. Check out the top 10 most anticipated drug launches of the year below. You can find last year's edition here." https://lnkd.in/gPgydAW7

The peptides and GLP-1 class of drugs that are offering breakthrough treatment for diabetes and obesity are estimated to be a $100 bn global opportunity by 2030. As patents keep expiring, companies like Biocon are well positioned to make the most of this opportunity. Speaking to Sohini Das and Aneeka Chatterjee, Kiran Mazumdar Shaw, executive chairperson, Biocon & Biocon Biologics, outlines how being vertically integrated puts Biocon in a strong position. Read the interview here https://mybs.in/2dY9WHY

Thoughts on this? >> Xencor’s $175M offering; Viridian to raise $150M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #productmarketing #biotech #pharma

Thoughts on this? >> SK Bioscience takes majority stake in CDMO for $244M; Ex-Lonza CEO joins Cytiva >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #productmarketing